This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (44)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Gerald R. Moress, MD; Anthony N. D'Agostino, MD; Leonard W. Jarcho, MD

Arch Neurol. 1967;16(4):377-384.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Vincristine INCRISTINE sulfate (Oncovin), an alkaloid isolated from Vinca rosea, has proven oncolytic activity in experimental and human neoplasms. Its main drawback in the treatment of human beings has been the severe neurotoxicity which produces numbness and anesthesia in the fingers and toes; paresthesias, and slapping gait¹; absent reflexes in the lower extremities, abducens palsy, visual disturbances, extensor weakness of the hands and feet²; persistent paresis³; bilateral foot drop and ataxia.⁴

The degree of neuromuscular intoxication and apparent reversibility vary. In one report symptoms continued as long as treatment was maintained but eventually disappeared six weeks after treatment was stopped.¹ In another study 14 of 16 patients who had received vincristine for more than two months lost the deep tendon reflexes of the lower extremities, but the period of observation was too short for comment on reversibility. In the same report muscle weakness was . . . [Full Text PDF of this Article]

Author Affiliations
Salt Lake City

From the departments of neurology and pathology, University of Utah College of Medicine Salt Lake City.

Footnotes
Submitted for publication Nov 5, 1966; accepted Nov 19.

Reprint requests to Department of Neurology, University of Utah College of Medicine, Salt Lake City 84112 (Dr. Jarcho).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?